Eli Lilly in Advanced Talks to Acquire AtaiBeckley for Psychedelic Mental Health Portfolio
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
The deal would boost Lilly’s psychedelic pipeline for treatment-resistant depression.
Novo Nordisk’s Wegovy pill is dominating early sales with 8x more prescriptions than Eli Lilly’s Foundayo.
The Florida-based surgical device maker faces margin pressures but sees strong interest from acquirers.
No formal bids yet as the ~$9B molecular diagnostics leader faces sector consolidation.
A whistleblower has accused Medicare Advantage insurer Alignment Healthcare of misclassifying expenses to inflate earnings.
Culper Research argues Tarsus is significantly overvalued, disputing the addressable market for its Demodex blepharitis drug XDEMVY.